Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Study Part A, and Open-label INX-08189 in Adjunctive (Interferon Free) Treatment With Daclatasvir and/or Ribavirin (Copegus®) in Study Part B, in Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects

Part A: The purpose of this study is to evaluate the safety and tolerability of INX-08189 and placebo with Peginterferon alfa-2a and Ribavirin during 12 weeks of treatment

Part B: The purpose of this study is to evaluate the safety and tolerability of INX-08189 with Ribavirin or INX-08189 with Daclatasvir or INX-08189 with Daclatasvir and Ribavirin

Study Overview

• Status: Terminated
• Conditions: Hepatitis C
• Intervention / Treatment: Drug: INX-08189; Drug: INX-08189; Drug: INX-08189; Biological: Pegylated interferon alfa-2a; Drug: Ribavirin; Drug: INX-08189; Drug: Placebo matching with INX-08189; Drug: Daclatasvir

Detailed Description

Data Monitoring Committee is appointed for Part A only

Masking: Part A of this study is Double blind and the Part B is Open Label

• Study Type: Interventional
• Enrollment (Actual): 210
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Anaheim, California, United States, 92801
      • Acri Phase One
    • La Jolla, California, United States, 92037
      • Scripps Health Dba Scripps Clinical Research Services
    • San Francisco, California, United States, 94115
      • Quest Clinical Research
  • Missouri
    • Kansas City, Missouri, United States, 64111
      • Kansas City Cancer Centers, Llc.
  • Oklahoma
    • Tulsa, Oklahoma, United States, 74104
      • Options Health Research, LLC
  • Texas
    • San Antonio, Texas, United States, 78215
      • Alamo Medical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Amendment 4: Genotype 1, 10 subjects at site 401.

• Males and females, 18 to 65 years of age inclusive with a body mass index (BMI) of at least 18 kg/m2 but not exceeding 36 kg/m2
• Diagnosed with chronic HCV at least 6 months prior to Visit 1 with medical documentation (e.g., prior PCR result, prior liver biopsy, prior genotyping, etc.), with a positive HCV viral load of at least 50,000 IU/mL at Visit 1 (screening) as measured by quantitative PCR
• Chronic genotype 2 or 3 HCV infection (per polymerase chain reaction [PCR] methodology)
• HCV treatment-naïve where "treatment-naïve" is defined as no prior treatment with IFN alfa 2a or 2b, Pegylated IFN alfa-2a, Ribavirin, or any HCV direct-acting anti-viral drugs
• Liver biopsy consistent with chronic HCV infection but with a classification of non-cirrhotic (and without classification of 'transition to cirrhosis or borderline cirrhosis') as judged by a pathologist (defined as Knodell ≤ 3, Metavir ≤ 2, Ishak ≤ 4, or Batts &Ludwig ≤ 2 ) within the last two years and before Visit 2 (biopsy can be done after Visit 1 and before Visit 2, within the screening period)
• Negative urine drug screen for drugs of abuse and methadone (via central lab-provided dipstick at site) at screening (Visit 1) (note: subjects with a valid prescription for a drug which can be abused [e.g., benzodiazepine, opiates] can be enrolled on the judgment of the investigator)
• Females will have a negative serum beta human chorionic gonadotropin (βHCG) pregnancy test at screening and a negative urine dipstick pregnancy test on Study Day 0 (visit 2)
• Agreement by both female subjects of childbearing potential and male subjects (who have not been surgically sterilized) to practice an acceptable method of birth control, which includes at least one barrier during the study and for at least 6 months after the cessation of treatment. Surgical sterilization of either the female or the male partner must have occurred at least 6 months prior to the first dose and females must be post-menopausal for 2 years to be considered of non-child-bearing potential. Acceptable contraceptive methods include one of the following: Oral and implantable hormonal contraceptives by the female partner for at least 3 months prior to the first dose of Study Drug with additional use of a barrier method, IUD in place for at least 6 months prior to first dose with additional use of barrier method. Acceptable barrier methods include either diaphragm with spermicide, and condom with spermicide. (Note: Abstinence is not an acceptable method of birth control, subjects who indicate sexual inactivity must agree to utilize an acceptable method of birth control in the event of sexual activity)
• Willing and able to complete all study visits and procedures, and able to effectively communicate with the investigator and other testing center personnel
• Signed informed consent form (ICF) executed prior to protocol screening assessments

Exclusion Criteria:

• Signs or symptoms of decompensated liver disease such as variceal bleeding, ascites, hepatic encephalopathy, active jaundice defined by an indirect bilirubin > 2, Alanine transaminase (ALT) or Aspartate aminotransferase (AST) laboratory values ≥ 10 times the upper limit of normal, or other evidence of decompensated liver disease, or hepatocellular carcinoma
• Chronic liver disease other than HCV not limited to Hepatitis B virus (HBV) [positive test for hepatitis B surface antigen (HBsAg)], hemochromatosis, auto-immune hepatitis, alcoholic liver disease or non-alcoholic fatty liver disease
• History of liver transplantation
• Co-infection with Human immunodeficiency virus (HIV) [positive test for anti-HIV Ab] or use of didanosine
• History of a heart attack, cardiac ischemia, heart disease, clinically symptomatic cardiac abnormalities, or blood clots, based on medical history or apparent on physical exam
• QTcF interval at Visit 1 of greater than or equal to 450 ms by Fridericia's correction, or a personal or family history of Torsades de Pointe
• History or presence of sarcoidosis or pancreatitis
• History or presence of severe pulmonary function impairment including severe (> GOLD stage III) chronic obstructive pulmonary obstructive disease, and moderate to severe asthma
• Uncontrolled diabetes mellitus as evidenced by HbA1C ≥ 8.5% at screening (Visit 1)
• Use of the following medications concurrently or within the 30 days prior to Screening (Visit 1) associated with QT prolongation: macrolides, antiarrhythmic agents, azoles, fluoroquinolones, and tricyclic anti-depressants (specifically excluded medication will be listed in protocol Section 6.8)
• Use of immunosuppressive or immune-modulating agents (including azathioprine, corticosteroids and immunosuppressive agents) or presence of an immunologically-mediated autoimmune disease (other than asthma) or history of solid organ or bone marrow transplantation (note: inhaled steroids for mild/moderate asthma and topical steroid for minor skin conditions allowed and washout period for per Oral (PO)/Intramuscular (IM)/ Intravenous (IV) corticosteroid use is 8 weeks; washout periods for other immunosuppressives determined by Medical Monitor)
• Use of strong CYP3A4-inhibiting protease inhibitors (specifically Atazanavir, Indinavir, Nelfinavir, Saquinavir, and Ritonavir), strong CYP3A4 inhibitors (specifically Clarithromycin, Itraconazole, Ketoconazole, Nefazodone, Telithromycin), or strong CYP3A4 inducers (specifically Rifampin, Efavirenz, Etravirine, Phenobarbital, Phenytoin, and Carbamazepine)
• Absolute neutrophil count of < 1800 cells/mm3, or platelet count < 130,000 cells/mm3, or hemoglobin < 12 g/dl for women and < 13 g/dl for men, or a history of anemia, sickle cell anemia, or thalassemia; (note: if baseline value within 5% of minimum qualifying value, one re-test allowed for the purpose of qualifying for study)
• A history or presence of abnormal thyroid function that is not adequately controlled [defined as Thyroid-stimulating hormone (TSH) levels less than 0.8 x lower limit of normal (LLN) or greater than 1.2 x the upper limit of normal (ULN)]
• Creatinine clearance < 50 mL/minute, serum creatinine concentration ≥ 1.5 times the ULN, or albumin ≤ 3 g/dl
• Presence or history of bipolar disorder, schizophrenia, psychosis, or unstable psychiatric condition, or hospitalization for psychiatric condition, or suicide attempt. (Note: Subjects with psychiatric conditions need to be adequately treated and on stable doses of appropriate medications for at least 3 months prior to Visit 1. History of suicidal ideation within prior 3 months is exclusionary)
• Any malignancy within the last 5 years other than treated cervical carcinoma in situ or treated basal cell carcinoma with no more than 20% risk of recurrence within 2 years
• Alcohol abuse by the assessment of the investigator within the past 2 years or an alcohol use pattern that will interfere with the study conduct
• Drug abuse by the assessment of the investigator within the last six months
• Pregnancy, current lactation in female subjects, or male subjects with partners who are pregnant, or females intending to become pregnant
• Major surgery within 30 days prior to Visit 1
• Participation in another clinical trial of an investigational drug or device within 6 months prior to Visit 1 unless that prior participation involved exposure only to placebo by clear and available documentation
• Donation of blood or plasma within 30 days prior to Visit 1 (not including routine laboratory assessments)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

9

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin; PART A Arm 1	Drug: INX-08189; Tablet, Oral, 25 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 50 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 100 mg, Once daily (QD), 12 weeks; Biological: Pegylated interferon alfa-2a; Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks; Drug: Ribavirin; Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks; Drug: INX-08189; Tablet, Oral, 200 mg, QD, 12 weeks
Experimental: 50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin; PART A Arm 2	Drug: INX-08189; Tablet, Oral, 25 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 50 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 100 mg, Once daily (QD), 12 weeks; Biological: Pegylated interferon alfa-2a; Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks; Drug: Ribavirin; Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks; Drug: INX-08189; Tablet, Oral, 200 mg, QD, 12 weeks
Experimental: 100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin; PART A Arm 3	Drug: INX-08189; Tablet, Oral, 25 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 50 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 100 mg, Once daily (QD), 12 weeks; Biological: Pegylated interferon alfa-2a; Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks; Drug: Ribavirin; Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks; Drug: INX-08189; Tablet, Oral, 200 mg, QD, 12 weeks
Placebo Comparator: Placebo + Pegylated interferon alfa-2a + Ribavirin; PART A Arm 4	Biological: Pegylated interferon alfa-2a; Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks; Drug: Ribavirin; Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks; Drug: Placebo matching with INX-08189; Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
Experimental: 100 mg INX-08189 + Ribavirin; PART B Arm 1	Drug: INX-08189; Tablet, Oral, 25 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 50 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 100 mg, Once daily (QD), 12 weeks; Drug: Ribavirin; Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks; Drug: INX-08189; Tablet, Oral, 200 mg, QD, 12 weeks
Experimental: 200 mg INX-08189 + Ribavirin; PART B Arm 2	Drug: INX-08189; Tablet, Oral, 25 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 50 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 100 mg, Once daily (QD), 12 weeks; Drug: Ribavirin; Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks; Drug: INX-08189; Tablet, Oral, 200 mg, QD, 12 weeks
Experimental: Daclatasvir + INX-08189 100 mg; PART B Arm 3	Drug: INX-08189; Tablet, Oral, 25 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 50 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 100 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 200 mg, QD, 12 weeks; Drug: Daclatasvir; Tablet, Oral, 60 mg, QD, 12 weeks; Other Names: BMS-790052
Experimental: Daclatasvir + INX-08189 200 mg; PART B Arm 4	Drug: INX-08189; Tablet, Oral, 25 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 50 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 100 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 200 mg, QD, 12 weeks; Drug: Daclatasvir; Tablet, Oral, 60 mg, QD, 12 weeks; Other Names: BMS-790052
Experimental: Daclatasvir + INX-08189 50 mg + Ribavirin; PART B Arm 5	Drug: INX-08189; Tablet, Oral, 25 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 50 mg, Once daily (QD), 12 weeks; Drug: INX-08189; Tablet, Oral, 100 mg, Once daily (QD), 12 weeks; Drug: Ribavirin; Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks; Drug: INX-08189; Tablet, Oral, 200 mg, QD, 12 weeks; Drug: Daclatasvir; Tablet, Oral, 60 mg, QD, 12 weeks; Other Names: BMS-790052

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part A: Change in Hepatitis C Viral Load Measurements at protocol specific timepoints		Weeks -6, 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 36, 48
Part B: proportion of subjects with SVR defined as HCV RNA ≤ LOQ (Limit of Quantitation)	SVR = Sustained virologic response; HCV RNA = Hepatitis C virus ribonucleic acid	At treatment weeks 12
Part B: proportion of subjects with SVR defined as HCV RNA ≤ LOQ		Post treatment week 12
Safety assessments is measured by Physical Exams, vital signs, laboratory assessments, ECGs, pregnancy test, viral resistance testing, adverse event assessment		up to 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects with RVR (Rapid Virologic Response), undetectable HCV RNA		At treatment weeks 4
Proportion of subjects with Complete EVR (Early Virologic Response), undetectable HCV RNA		At treatment weeks 12
Proportion of subjects with Extended RVR		At treatment weeks 4 and 12
Proportion of subjects with SVR24	SVR24 = sustained virologic response at 24 weeks after the cessation of treatment	Post treatment week 24

Collaborators and Investigators

• Sponsor: Bristol-Myers Squibb

Publications and helpful links

Helpful Links

• BMS clinical trial educational resource

Study record dates

Study Major Dates

• Study Start: May 1, 2012
• Primary Completion (Actual): August 1, 2013
• Study Completion (Actual): August 1, 2013

Study Registration Dates

• First Submitted: August 25, 2011
• First Submitted That Met QC Criteria: August 29, 2011
• First Posted (Estimate): August 30, 2011

Study Record Updates

• Last Update Posted (Estimate): November 4, 2015
• Last Update Submitted That Met QC Criteria: October 12, 2015
• Last Verified: October 1, 2015

More Information

Terms related to this study

• Keywords: Chronic Hepatitis; Hepatitis C Virus; Inhibitex
• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Hepatitis; Hepatitis C; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Antimetabolites; Antineoplastic Agents; Immunologic Factors; Interferons; Interferon-alpha; Ribavirin; Peginterferon alfa-2a; Interferon alpha-2
• Other Study ID Numbers: AI472-003; INH-189-003 (Other Identifier: INH-189-003)